273 related articles for article (PubMed ID: 25980593)
21. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
Gao N; Zhang T; Ji J; Xu KF; Tian X
Orphanet J Rare Dis; 2018 Aug; 13(1):134. PubMed ID: 30107845
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic targeting of mTOR in tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
[TBL] [Abstract][Full Text] [Related]
24. The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.
El-Chemaly S; Henske EP
Expert Rev Respir Med; 2015 Apr; 9(2):195-204. PubMed ID: 25757365
[TBL] [Abstract][Full Text] [Related]
25. EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.
Taveira-DaSilva AM; Moss J
Expert Opin Orphan Drugs; 2016; 4(4):369-378. PubMed ID: 27833825
[TBL] [Abstract][Full Text] [Related]
26. The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis.
Courtwright AM; Goldberg HJ; Henske EP; El-Chemaly S
Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096282
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium.
Issaka RB; Oommen S; Gupta SK; Liu G; Myers JL; Ryu JH; Vlahakis NE
Am J Pathol; 2009 Oct; 175(4):1410-20. PubMed ID: 19717640
[TBL] [Abstract][Full Text] [Related]
28. mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis.
Yu J; Henske EP
Lymphat Res Biol; 2010 Mar; 8(1):43-9. PubMed ID: 20235886
[TBL] [Abstract][Full Text] [Related]
29. Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
Nascimento ECTD; Baldi BG; Mariani AW; Annoni R; Kairalla RA; Pimenta SP; da Silva LFF; Carvalho CRR; Dolhnikoff M
Respir Res; 2018 May; 19(1):83. PubMed ID: 29739412
[TBL] [Abstract][Full Text] [Related]
30. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
[TBL] [Abstract][Full Text] [Related]
31. [Lymphangioleiomyomatosis - new concepts on pathogenesis, diagnosis and treatment].
Sobiecka M
Wiad Lek; 2016; 69(2 Pt 1):123-9. PubMed ID: 27421126
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
[TBL] [Abstract][Full Text] [Related]
33. Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis.
Mohammadieh AM; Bowler SD; Silverstone EJ; Glanville AR; Yates DH
Med J Aust; 2013 Jul; 199(2):121-3. PubMed ID: 23879512
[TBL] [Abstract][Full Text] [Related]
34. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
35. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
[TBL] [Abstract][Full Text] [Related]
36. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.
Glasgow CG; Avila NA; Lin JP; Stylianou MP; Moss J
Chest; 2009 May; 135(5):1293-1300. PubMed ID: 19420197
[TBL] [Abstract][Full Text] [Related]
37. Effect of mTOR inhibitors on the mortality and safety of patients with lymphangioleiomyomatosis on the lung transplantation waitlist: A retrospective cohort study.
Sakurai T; Kanou T; Funaki S; Fukui E; Kimura T; Ose N; Inoue Y; Shintani Y
Respir Investig; 2024 Jul; 62(4):657-662. PubMed ID: 38761480
[TBL] [Abstract][Full Text] [Related]
38. Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis.
Huang YL; Chen PR; Lai YJ; Hsu HH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445268
[TBL] [Abstract][Full Text] [Related]
39. Durability of Sirolimus for Lymphangioleiomyomatosis.
Martirossian A; Shah S; Carrete L; Valle J; Valentine V
Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
[TBL] [Abstract][Full Text] [Related]
40. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
